252 Immune-related adverse events associated with immune checkpoint inhibitor therapy are associated with enhanced survival and disease-specific incidence

• Trisha Wise-Draper,
• Eric Vick,
• Inas Abuali,
• Andrew Kelleher,
• Sarah Ludvigsen,
• Nathanael Moore,
• Nicholas Arias,
• Shuchi Gulati

Affiliations

Trisha Wise-Draper

Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

Eric Vick

2University of Cincinnati Medical Center, Cincinnati, OH, USA

Inas Abuali

1University of Cincinnati Medical Center and Cancer Center, Cincinnati, OH, USA

Andrew Kelleher

2University of Cincinnati Medical Center, Cincinnati, OH, USA

Sarah Ludvigsen

2University of Cincinnati Medical Center, Cincinnati, OH, USA

Nathanael Moore

2University of Cincinnati Medical Center, Cincinnati, OH, USA

Nicholas Arias

3University of Cincinnati, Cincinnati, OH, USA

Shuchi Gulati

1University of Cincinnati Medical Center and Cancer Center, Cincinnati, OH, USA